Sources: Amgen mulling bid for Actelion

Rumors of a possible takeover of Switzerland's Actelion, a Roche spinout, turned red hot after the company merely noted that it is always engaged in routine talks with other biopharma companies. And Amgen fanned the flames when it declined to comment on rumors that it is angling to acquire the company. According to Bloomberg, Amgen is considering a bid for Actelion to gain drugs for rare diseases. Report